ERIS Lifesciences Ltd
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
- Market Cap ₹ 20,710 Cr.
- Current Price ₹ 1,521
- High / Low ₹ 1,594 / 816
- Stock P/E 58.9
- Book Value ₹ 210
- Dividend Yield 0.50 %
- ROCE 12.2 %
- ROE 12.9 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 71.8 days to 39.7 days
Cons
- Stock is trading at 7.01 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | |
414 | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | |
Operating Profit | 95 | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,017 |
OPM % | 19% | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% |
9 | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | |
Interest | 0 | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 |
Depreciation | 5 | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 |
Profit before tax | 98 | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 |
Tax % | 28% | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% |
71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | |
EPS in Rs | 5,121.45 | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 |
Dividend Payout % | 0% | 0% | 63% | 0% | 0% | 0% | 13% | 21% | 20% | 26% | 0% | 28% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 22% |
3 Years: | 29% |
TTM: | 44% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 4% |
3 Years: | -5% |
TTM: | -10% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 27% |
1 Year: | 62% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 18% |
3 Years: | 16% |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.14 | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 176 | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 |
1 | 1 | 0 | 1 | 377 | 176 | 0 | 7 | 84 | 877 | 2,781 | 2,478 | |
94 | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,375 | 1,701 | |
Total Liabilities | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,742 | 7,033 |
75 | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,328 | 5,307 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 0 |
Investments | 84 | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 |
112 | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,659 | |
Total Assets | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,742 | 7,033 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | |
-83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -80 | |
-2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 | |
Net Cash Flow | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 104 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 16 | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 |
Inventory Days | 166 | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 |
Days Payable | 138 | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 258 | 170 |
Cash Conversion Cycle | 43 | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 0 | 59 |
Working Capital Days | 7 | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 76 | 92 | 83 | 40 |
ROCE % | 64% | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Earnings call recording for Q4 FY25 results available on company website.
-
Revision In Outcome Of Board Meeting
1d - Eris Lifesciences reports audited FY25 consolidated results; minor correction in asset disclosure, no profit impact.
-
Financial Results For Quarter And Year Ended March 31, 2025
1d - Eris Lifesciences approved audited FY25 financials; appointed secretarial and cost auditors; declared NCD interest record date.
- Announcement under Regulation 30 (LODR)-Investor Presentation 1d
-
Board Meeting Outcome for Outcome Of Board Meeting
1d - Eris Lifesciences approved audited FY25 financial results; appointed secretarial and cost auditors; declared NCD interest record date.
Annual reports
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Mar 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Mar 2023TranscriptPPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Mar 2021TranscriptPPT
-
Jan 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
Market Position
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market. [1]